Federated Hermes’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Federated Hermes’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4	Closed	-$1.25K	–	2206
2023 Q1	$1.25K	Sell	4 -1,248	-100%	-$244K	﹤0.01%	2032
2022 Q4	$160K	Sell	1,252 -1,323	-51%	-$221K	﹤0.01%	1593
2022 Q3	$685K	Sell	2,575 -68	-3%	-$25.9K	﹤0.01%	1242
2022 Q2	$1.17M	Buy	2,643 +575	+28%	+$406K	﹤0.01%	1084
2022 Q1	$2.56M	Buy	2,068 +1,537	+289%	+$2.09M	0.01%	965
2021 Q4	$1.34M	Buy	531 +220	+71%	+$1.34M	﹤0.01%	1169
2021 Q3	$5.69M	Buy	311 +153	+97%	+$2.43M	0.01%	795
2021 Q2	$1.68M	Buy	+158	New	+$1.32M	﹤0.01%	1149
2019 Q4	–	Hold	0	–	-$2K	–	2289
2019 Q3	–	Hold	0	–	–	–	2041

Other funds holding IRLA

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KAM

Knightsbridge Asset Management Newport Beach, California $762M AUM 59.13% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes's IRLA Position: Q2 2023 in Review

Federated Hermes sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2023, closing a stake of 4 shares — an estimated $1.25K sold.

Federated Hermes first reported a position in IRLA in Q2 2021 and held it in 8 quarters. The position peaked at $5.69M in Q3 2021. 38 funds tracked by Wall St. Rank hold IRLA as of Q2 2023.

Federated Hermes reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Federated Hermes sold 4 IRulya Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $1.25K.
Federated Hermes first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Federated Hermes's IRulya Therapeutics Inc. Common Stock position peaked at $5.69M in Q3 2021.
38 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2023.

Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.